CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended darolutamide, an oral androgen receptor inhibitor (ARi), plus ADT in combination with docetaxel for marketing authorization in the European Union (EU) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).

from Breaking World Pharma News https://ift.tt/5RFlQL8